Facchinetti et al. have reviewed in‐depth ROS‐1 inhibition in the context of oncogene addiction in NSCLC.84ROS‐1 has been shown to share certain characteristics with the ALK oncogene; however, there are also distinct disparities between the two fusion genes.84 When more common genetic aberrations, such as EGFR‐, KRAS‐, and ALK‐mutations, are absent it is mandatory to search for ROS‐1 rearrangement. This evidence concerns the gene ALK and non-small cell lung carcinoma.